December 19, 2001
NOVARTIS AND PALADIN ENTER INTO AGREEMENT FOR THE CANADIAN RIGHTS TO DERMATOLOGY PRODUCTS
(Also in PDF format)

December 12, 2001
PALADIN NAMED ONE OF CANADA'S 50 BEST MANAGED COMPANIES
(Also in PDF format)

December 10, 2001
PALADIN ANNOUNCES TERMINATION OF SYNSORB-CD DEVELOPMENT PROGRAM
(Also in PDF format)

December 4, 2001
PALADIN ANNOUNCES TPD APPROVAL FOR ADDITIONAL METHANOL POISONING INDICATION FOR ANTIZOL^®
(Also in PDF format)

November 20, 2001
GENERIC COMPETITION OF URISPAS^® EXPECTED IN 2002
(Also in PDF format)

November 8, 2001
PALADIN LABS ACHIEVES RECORD RESULTS FOR THIRD QUARTER
(Also in PDF format)

November 5, 2001
PALADIN & NOVARTIS SIGN LICENSE AGREEMENT FOR CANADIAN RIGHTS TO ROGITINE^®
(Also in PDF format)

August 30, 2001
PALADIN LABS ANNOUNCES THE ACQUISITION OF HYPERTHYROID DRUG FROM MERCK FROSST
(Also in PDF format)

August 9, 2001
PALADIN LABS ANNOUNCES RECORD SECOND QUARTER FINANCIAL RESULTS
(Also in PDF format)

July 16, 2001
PALADIN LABS ANNOUNCES APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER
(Also in PDF format)

May 3, 2001
PALADIN LABS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
(Also in PDF format)

May 1, 2001
NOTICE OF PALADIN LABS INC. CONFERENCE CALL
(Also in PDF format)

March 29, 2001
PALADIN LABS ANNOUNCES YEAR-END FINANCIAL RESULTS
(Also in PDF format)

March 2, 2001
PALADIN SIGNS MARKETING AND DISTRIBUTION AGREEMENT FOR FIORINAL^®
(Also in PDF format)

February 28, 2001
PALADIN ANNOUCES MANAGEMENT CHANGE
(Also in PDF format)

February 7, 2001
PALADIN LABS INC. APPOINTS NEW DIRECTOR
(Also in PDF format)

February 2, 2001
PALADIN COMMITS TO PROVIDING CANADIAN WOMEN WITH ACCESS TO PLAN BT THE ONLY DEDICATED ORAL EMERGENCY CONTRACEPTIVE MARKETED IN CANADA
(Also in PDF format)

February 1, 2001
PALADIN LICENSES CANADIAN RIGHTS TO OESCLIM^® FROM GROUPE FOURNIER
(Also in PDF format)